A major study involving more than 120,000 older adults has found that commonly prescribed osteoporosis drugs may be associated with a significantly reduced risk of Alzheimer’s disease and other forms of dementia. According to the findings, patients taking these bone-strengthening medications showed up to a 24 percent lower likelihood of developing dementia compared with those who did not use them. The research, which drew on a large cohort of elderly participants, adds to a growing body of evidence suggesting that treatments developed for one condition may offer unexpected benefits for the aging brain. The magnitude of the association surprised investigators and is likely to prompt closer scrutiny of the underlying biological mechanisms.
Researchers cautioned that the observational nature of the study means it cannot establish a direct cause-and-effect relationship between osteoporosis drugs and dementia prevention. Factors such as patient health status, socioeconomic background, and duration of medication use could influence the results, and further randomized controlled trials would be needed to confirm whether the drugs genuinely protect cognitive function. Nevertheless, the findings raise the possibility that existing, widely available medications could be repurposed as a low-cost strategy to slow the onset of dementia, a condition affecting tens of millions worldwide. Public health experts said the results warrant attention but stressed that patients should not alter their prescriptions without consulting physicians.
Independent reporting synthesized from primary wires and global correspondents.